2025-10-03 - Analysis Report
Okay, here's an analysis of SDGR (Schrodinger Inc.) based on the data provided, formatted for clarity and including key metrics and insights:

**Report on Schrodinger Inc. (SDGR)**

Schrodinger Inc. is a company that develops software for drug discovery and materials science.

**1. Performance vs. S&P 500 (VOO)**

*   **SDGR Cumulative Return:** -53.61%
*   **VOO Cumulative Return:** 65.72%
*   **Absolute Divergence (Current):** -119.3%
*   **Relative Divergence (Current):** 0.9%

    *   This indicates SDGR has significantly underperformed the S&P 500 over the observed period. The relative divergence suggests it's near the lowest end of its historical divergence range.

**Alpha, Beta Analysis**

| Year       | CAGR    | MDD     | Alpha   | Beta   | Cap(B) |
|------------|---------|---------|---------|--------|--------|
| 2020-2022  | -70.0%  | 78.2%   | -76.0%  | 0.0    | 1.3    |
| 2021-2023  | -57.0%  | 81.0%   | -59.0%  | -0.0   | 2.5    |
| 2022-2024  | 6.0%   | 81.0%   | -14.0%  | -0.0   | 1.4    |
| 2023-2025  | -2.0%  | 82.6%   | -64.0%  | -0.0   | 1.4    |

*   **CAGR:** Consistently negative CAGR values point to significant losses over different periods.
*   **MDD:** Very high Maximum Drawdown (MDD) indicates substantial risk and volatility.
*   **Alpha:** Negative alpha suggests the stock has underperformed relative to its benchmark (S&P 500) after accounting for risk.
*   **Beta:** Beta values near zero suggest a very low correlation with the overall market.

**2. Recent Stock Price Movement**

*   **Current Price:** $19.60
*   **Last Market Data:** {'price': 21.45, 'previousClose': 21.21, 'change': 1.13}
*   **5-Day Moving Average:** $19.21
*   **20-Day Moving Average:** $19.12
*   **60-Day Moving Average:** $20.05

    *   The price increased at the last market.

**3. Market Risk Indicators & Expected Return**

*   **Market Risk Indicator (MRI):** 0.9 (Medium to High Investment Recommended)
*   **RSI:** 51.27 (Neutral)
*   **PPO:** 0.47 (Slightly Bullish)
*   **Hybrid Signal:** cash_0%_Buy 100% of cash (52 shares - Very Safe - MRI:0.90)
*   **Recent (20-Day) Relative Divergence Change:** 0.5 (+) - Indicates short-term upward momentum.
*   **Expected Return:** -6099.0% (Very Negative)

    *   MRI suggests medium-to-high investment, but the negative expected return is a major red flag.

**4. Recent News & Significant Events**

*   **Oct 1, 2025:** Argus Research raises target price to $21.00.
*   **Sep 18, 2025:** Reports Inducement Grants under Nasdaq Listing Rule.
*   **Sep 11, 2025:** Evaluating Valuation as Market Sentiment Remains Quiet.
*   **Sep 9, 2025:** Analysts expect potential rally of 40.43%.
*   **Aug 27, 2025:** Presentation at Morgan Stanley Global Healthcare Conference.

    *   The news is mixed, with some positive analyst outlooks but also corporate announcements that need further scrutiny.

**4-2. Analyst Opinions**

*   **Consensus:** Buy
*   **Mean Rating:** 1.56 (~Buy)
*   **Number of Opinions:** 10
*   **Target Price (avg/high/low):** $27.20 / $33.00 / $19.00

**5. Recent Earnings Analysis**

| Date       | EPS   | Revenue |
|------------|-------|---------|
| 2025-08-06 | -0.59 | 0.05 B$ |
| 2025-05-07 | -0.82 | 0.06 B$ |
| 2024-11-12 | -0.52 | 0.04 B$ |
| 2024-07-31 | -0.74 | 0.05 B$ |
| 2025-08-06 | -0.74 | 0.05 B$ |

*   Consistently negative EPS figures raise concerns about profitability.
*   Revenue figures are relatively stable but low.

**6. Financial Information**

Revenue and Profitability:

| Quarter    | Revenue | Profit Margin |
|------------|---------|---------------|
| 2025-06-30 | $0.05B | 47.77%        |
| 2025-03-31 | $0.06B | 52.26%        |
| 2024-12-31 | $0.09B | 72.61%        |
| 2024-09-30 | $0.04B | 50.24%        |
| 2024-06-30 | $0.05B | 66.20%        |

Capital and Profitability:

| Quarter    | Equity  | ROE       |
|------------|---------|-----------|
| 2025-06-30 | $0.34B | -12.59%   |
| 2025-03-31 | $0.37B | -16.01%   |
| 2024-12-31 | $0.42B | -9.54%    |
| 2024-09-30 | $0.45B | -8.49%    |
| 2024-06-30 | $0.47B | -11.40%   |

*   While profit margins appear relatively high, declining equity and negative ROE indicate potential financial difficulties.

**7. Overall Analysis & Summary**

*   SDGR has significantly underperformed the S&P 500.
*   Financial metrics (EPS, ROE) are concerning, indicating unprofitability.
*   Analysts have a generally positive outlook, but target prices vary.
*   The MRI suggests medium-to-high investment appropriateness, but this contrasts sharply with the highly negative expected return.
*   The recent price increase suggests short-term upward momentum.

**Conclusion:**

Based on the data provided, investing in SDGR carries significant risk. While analyst opinions are generally positive, the company's financial performance and negative expected return raise serious concerns. A deeper dive into the company's business model, cash flow, and growth prospects is warranted before considering an investment. The recent price increase, if sustainable, might indicate a potential turnaround, but it's too early to confirm.
